The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder
Orli Schwartz, G. Paul Amminger, Bernhard T Baune, Gillinder Bedi, Michael Berk, Sue Cotton, Rothanthi Daglas‐Georgiou, Nick Glozier, Ben J. Harrison, Daniel Francis Hermens, Emma L. M. Jennings, Jim Lagopoulos, Colleen Loo, Sumudu Rasangi Mallawaarachchi, Donel Martin, Bethany Phelan, Nikki Read, Anthony Rodgers, Lianne Schmaal, Andrew Alexander Somogyi, Lily Thurston, Amber Weller, Christopher G. Davey
Trials October 24, 2023 DOI: 10.1186/s13063-023-07631-3 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Young people aged 16 to 25 years with moderate-to-severe major depressive disorder |
| Interventions | Ketamine Midazolam |
| Dose | low-dose |
| Duration | 4-week treatment course; follow-up at 8 and 26 weeks from treatment commencement |
| Measures | Montgomery-Åsberg Depression Rating Scale (MADRS) |
| Topics | Depression Esketamine Ketamine |
| Citations | 1 |
| Key findings | The abstract describes the planned SKY-D trial, which will determine whether a 4-week course of low-dose subcutaneous ketamine is an effective adjunct to treatment-as-usual for young people with moderate-to-severe major depressive disorder. No results are reported. |
Abstract
Background: Existing treatments for young people with severe depression have limited effectiveness. The aim of the Study of Ketamine for Youth Depression (SKY-D) trial is to determine whether a 4-week course of low-dose subcutaneous ketamine is an effective adjunct to treatment-as-usual in young people with major depressive disorder (MDD).
Methods: SKY-D is a double-masked, randomised controlled trial funded by the Australian Government's National Health and Medical Research Council (NHMRC). Participants aged between 16 and 25 years (inclusive) with moderate-to-severe MDD will be randomised to receive either low-dose ketamine (intervention) or midazolam (active control) via subcutaneous injection once per week for 4 weeks. The primary outcome is change in depressive symptoms on the Montgomery-Åsberg Depression Rating Scale (MADRS) after 4 weeks of treatment. Further follow-up assessment will occur at 8 and 26 weeks from treatment commencement to determine whether treatment effects are sustained and to investigate safety outcomes.
Discussion: Results from this trial will be important in determining whether low-dose subcutaneous ketamine is an effective treatment for young people with moderate-to-severe MDD. This will be the largest randomised trial to investigate the effects of ketamine to treat depression in young people.
Trial Registration: Australian and New Zealand Clinical Trials Registry ID: ACTRN12619000683134. Registered on May 7, 2019. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377513 .
Comparable studies
Other randomized controlled trials on ketamine for depression, most cited first.
Citations in the library
Cites 26
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- Mechanisms of Ketamine Action as an Antidepressant Molecular Psychiatry March 13, 2018
- Measurement of dissociative states with the Clinician‐Administered Dissociative States Scale (CADSS) Journal of Traumatic Stress 1998
- The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis American Journal of Psychiatry October 3, 2017
- Mapping the self in the brain's default mode network Neuroimage February 15, 2016
and 21 more in the library